Sun Pharmaceutical Industries Limited — Board Meeting, 31-07-2025: Outcome of Board Meeting

Sun Pharma's board has approved the financial results for Q1 FY26. Consolidated gross sales surged 10.1% YoY to Rs 13,786.1 crore, with adjusted net profit up 5.7% YoY at Rs 2,996.1 crore. Reported net profit of Rs 2,278.6 crore was impacted by significant exceptional charges, including R&D discontinuation and a litigation settlement. India sales showed strong momentum. The board also made key committee appointments: Dilip Shanghvi joined Nomination & Remuneration, Aalok Shanghvi joined Stakeholders Relationship & Risk Management, and Vidhi Shanghvi joined CSR. Sudhir Valia retired from multiple committees.